<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03062956</url>
  </required_header>
  <id_info>
    <org_study_id>MYK-491-001</org_study_id>
    <nct_id>NCT03062956</nct_id>
  </id_info>
  <brief_title>A Single Ascending Dose Study Assessing the Safety, Tolerability, PK and PD of MYK-491</brief_title>
  <official_title>Randomized, Placebo-Controlled Study of Safety, Tolerability, Preliminary Pharmacokinetics and Pharmacodynamics of Single Ascending Oral Doses of MYK-491 in Healthy Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MyoKardia, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MyoKardia, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Up to 72 healthy volunteers will be given a single dose of MYK-491 or placebo and be
      monitored for safety and tolerability over a 7 day period.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Up to 72 healthy volunteers will be given a single dose of MYK-491 or placebo and be
      monitored for safety and tolerability over a 7 day period. After the 28 day screening period,
      the eligible subject will be admitted to the clinical site and will receive a single dose of
      study drug or placebo. Subjects will be confined to the clinical site for five days (Day -1
      to Day 4) and will return to the clinic on Day 7 for a safety follow-up.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 16, 2017</start_date>
  <completion_date type="Actual">November 28, 2017</completion_date>
  <primary_completion_date type="Actual">November 28, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Subjects will be randomized 6:2 to MYK-491:placebo within each cohort.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability assessments will include treatment emergent AEs and SAEs, ECG recordings, vital signs, hs-troponin 1 concentrations, laboratory abnormalities and physical exam abnormalities</measure>
    <time_frame>7 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma drug concentration (Cmax)</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma concentration (Tmax)</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve (AUC)</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>First-order terminal elimination half-life (t1/2)</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean retention time (MRT)</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>The change from baseline in LVFS, LVEF, LVSV and SET by TTE</measure>
    <time_frame>7 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>SET while using photoplethysmography</measure>
    <time_frame>7 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Relationship between MYK-491 plasma concentrations/PK parameters and PD parameters</measure>
    <time_frame>7 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Plasma concentrations of metabolites of MYK-491 in plasma and urine</measure>
    <time_frame>7 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Relationship between MYK-491 plasma concentration and QTc interval</measure>
    <time_frame>7 days</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Dilated Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>Single oral dose of MYK-491</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single-dose, oral suspension</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single oral dose of placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>single-dose, oral suspension</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MYK-491 or placebo</intervention_name>
    <description>Oral suspension</description>
    <arm_group_label>Single oral dose of MYK-491</arm_group_label>
    <arm_group_label>Single oral dose of placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Weight between 60 and 90 kg inclusive

          -  Resting heart rate of &lt; 80 beats per minute

          -  Documented LVEF greater than or equal to 55% during Screening

          -  Normal electrocardiogram (ECG) at Screening

          -  Normal acoustic windows on transthoracic echocardiograms at Screening

          -  All safety laboratory parameters within normal limits at Screening

          -  History or evidence of another clinically significant disorder, in the opinion of the
             investigator.

        Exclusion Criteria:

          -  Active infection

          -  History of coronary artery disease

          -  History of malignancy with the exception of in situ cervical cancer more than 5 years
             prior to Screening or surgically-excised non-melanomatous skin cancers more than 2
             years prior to Screening

          -  Positive serology tests at screening

          -  Current use of tobacco or nicotine-containing products exceeding 10 per day.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jason Lickliter, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nucleus Network</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nucleus Network</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 16, 2017</study_first_submitted>
  <study_first_submitted_qc>February 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 24, 2017</study_first_posted>
  <last_update_submitted>March 21, 2018</last_update_submitted>
  <last_update_submitted_qc>March 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Cardiomyopathy, Dilated</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

